Orion Corporation has broadened its partnership with Glykos, focusing on the development of antibody-drug conjugates (ADCs).
Under the research partnership and licensing agreement, Orion will obtain access to Glykos’ ADC technologies for probable expansion into three new programmes beyond those specified in the original agreement.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataOrion will oversee target selection, research, development and commercialisation of future ADCs, concentrating on solid tumours.
Orion innovative medicines and research and development executive vice-president Outi Vaarala stated: “This successful collaboration with Glykos allows us to continue leveraging their advanced ADC technology and underscores our commitment to developing new treatment options for cancer patients.”
The financial conditions outlined in the extended agreement covering the three new ADC projects remain consistent with those specified in the original agreement signed in January 2024 for the initial three projects.
Glykos will receive milestone payments tied to both the development and sales of these ADCs.
The company is also entitled to royalties from commercial sales from the three ADC programmes.
Glykos CEO Juhani Saarinen stated: “The extension of our agreement with Orion highlights the potential of our ADC technology. We are excited to expand our collaboration with Orion, whose expertise in cancer therapies and strong clinical development capabilities are crucial for bringing new, effective treatments to cancer patients.”
In September 2024, Orion entered a partnership with Aitia to leverage AI in drug discovery and simulation in the oncology field.
Through their collaboration, the companies aimed to develop new Gemini Digital Twins – innovative tools designed to enhance cancer treatment strategies and address translational questions and develop drug candidates for multiple cancer indications.
ADC content on Pharmaceutical Technology (Or Clinical Trials Arena) is supported by Syngene. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
